Brief: Compass Pathways Successfully Achieves Primary Endpoint In Second Phase 3 Trial Evaluating Comp360 Psilocybin
17/02/2026 11:43
Feb 17 (Reuters) - Compass Pathways PLC CMPS.O: COMPASS PATHWAYS SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT IN SECOND PHASE 3 TRIAL EVALUATING COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION COMPASS PATHWAYS PLC - COMP360 SHOWS WELL-TOLERATED AND SAFE PROFILE COMPASS PATHWAYS PLC - REQUESTS FDA MEETING FOR ROLLING SUBMISSION Source text: ID:nBw6fCmxZa Further company coverage: CMPS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on COMPASS Pathways
See all newsBrief: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Trump's psychedelic drug order boosts investor interest with promise of faster reviews
UK's Compass Pathways Q1 operating income beats estimates as expenses fall
Health Rounds: Researchers gain new insight into how psychedelics affect the brain
U.S. STOCKS ON THE MOVE-Eli Lilly, Compass Pathways, Charter Communications